29/04/2015 - 22:00 A new agent targeting tumors that develop resistance to EGFR tyrosine kinase inhibitors proved to be “highly active” in a phase I clinical trial i... More » Visit websiteField of Interest: OncologyCategories: CME-candidateCHEST || Clinical NewsCHEST || NewsCHEST || Lung CancerONCR || NewsONCR || LungFPN || NewsFPN || OncologyNews Feed: Internal Medicine News - Oncology